Stella Pharma Corporation

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA	Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, adenoma, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, fibrosarcoma, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, non-small cell lung carcinoma, peripheral nervous system disorder, peripheral nervous system neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder	Enrolling by invitation	Phase 1 / Phase 2	2025-11-19		NCT06603987
A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA	Unresectable Angiosarcoma	Active, not recruiting	Phase 2	2025-04-09		NCT05601232

Clinical trials